Abstracts tagged "Bone density"

Abstract Number: 1024 • 2016 ACR/ARHP Annual Meeting
Superior Gains in Bone Mineral Density and Estimated Strength at the Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of a Phase 3, Open-Label Clinical Trial
B Langdahl¹, C Libanati², DB Crittenden³, MA Bolognese⁴, JP Brown⁵, NS Daizadeh³, K Engelke⁶, HK Genant⁷, S Goemaere⁸, Lars Hyldstrup⁹, E Jodar-Gimeno¹⁰, TM Keaveny¹¹, D Kendler¹², P Lakatos¹³, J Maddox³, J Malouf¹⁴, FE Massari¹⁵, JF Molina¹⁶, MR Ulla¹⁷ and A Grauer³, ¹Aarhus University Hospital, Aarhus, Denmark, ²UCB Pharma, Brussels, Belgium, ³Amgen Inc., Thousand Oaks, CA, ⁴Bethesda Health Research Center, Bethesda, MD, ⁵Laval University and CHU de Québec (CHUL) Research Centre, Quebec City, QC, Canada, ⁶BioClinica Inc., Hamburg, Germany, ⁷Department of Radiology, University of California San Francisco, San Francisco, CA, ⁸Ghent University Hospital, Gent, Belgium, ⁹Hvidovre University Hospital, Hvidovre, Denmark, ¹⁰Servicio de Endocrinología, Hospital Universitario Quirón, Madrid, Spain, ¹¹University of California at Berkeley, Berkeley, CA, ¹²University of British Columbia, Vancouver, BC, Canada, ¹³Department of Medicine, Semmelweis University, Budapest, Hungary, ¹⁴Universitat Autònoma de Barcelona, Barcelona, Spain, ¹⁵Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina, ¹⁶Reumalab Centro Integral de Reumatologia, Medellin, Colombia, ¹⁷Instituto Latinoamericano de Investigaciones Médicas, Córdoba, Argentina
Background/Purpose: STRUCTURE was a phase 3, open-label study evaluating the effect of romosozumab or teriparatide for 12 months in women with postmenopausal osteoporosis transitioning from…
Abstract Number: 1531 • 2016 ACR/ARHP Annual Meeting
Decrease in Bone Mineral Density during Three Months of Early RA Measured By DXR Predicts Radiographic Joint Damage after One Year
Michael Ziegelasch¹, Kristina Forslind², Thomas Skogh³, Katrine Riklund⁴, Alf Kastbom⁵ and E. Berglin⁶, ¹Rheumatology/AIR, Linköping, Sweden, ²Department of Medicine, Helsingborgs Lasarett, Section of Rheumatology, Helsingborg, Sweden, ³IKE/Rheumatology, Linköping University, Linköping, Sweden, ⁴Departments of Diagnostic radiology, Umeå university, Umeå, Sweden, ⁵Department of Clinical and Experimental Medicine, Rheumatology/AIR, Linköping, Sweden, ⁶Department of Publiic Health and Clinical Medicin/Rheumatology, Umeå university, Umea, Sweden
Background/Purpose: Digital X-ray radiogrammetry (DXR) is a method to calculate peripheral bone mineral density (BMD) which calculates BMD of the hands (DXR-BMD). The aim…
Abstract Number: 352 • 2015 ACR/ARHP Annual Meeting
Low Bone Density Is Associated with Atherosclerotic Disease in Patients with Psoriatic Arthritis
Eirik Ikdahl^1,2, Hege Kilander Høiberg³, Silvia Rollefstad², Andreas P Diamantopoulos^4,5, Grunde Wibetoe², Arthur Kavanaugh⁶, Inge C Olsen⁷, Tore K. Kvien⁷, Anne Grete Semb⁸ and Glenn Haugeberg⁹, ¹Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, ⁴Rheumatology, Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway, ⁵Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ⁶University of California San Diego, La Jolla, CA, ⁷Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁸Diakonhjemmet Hospital, Oslo, Norway, ⁹Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway
Background/Purpose: There is an evidence vacuum concerning the mechanisms underlying the high atherosclerotic cardiovascular disease (ASCVD) burden in patients with psoriatic arthritis (PsA). In the…
Abstract Number: 376 • 2015 ACR/ARHP Annual Meeting
The Relationships Between Bone Mineral Density and Radiographic Features of Hand or Knee Osteoarthritis in Older Adults: Data from the Dong-Gu Study
Kyung-Eun Lee¹, Lihui Wen¹, Yi-Rang Yim¹, Ji-Eun Kim¹, Jeong-Won Lee¹, Dong-Jin Park², Shin-Seok Lee¹ and Shin-Seok Lee's group, ¹Chonnam National University Medical School and Hospital, Gwangju, South Korea, ²Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea
Background/Purpose: The relationship between osteoarthritis (OA) and osteoporosis has exhibited contradictory features over the past four decades. We evaluated this relationship using separate analysis of…
Abstract Number: 579 • 2015 ACR/ARHP Annual Meeting
Methotrexate Does Not Influence 1-Year Bone Mineral Density in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Richard Koch¹, Thomas Barnetche², Adeline Ruyssen-Witrand¹, Alain Cantagrel¹, Arnaud Constantin³ and Yannick Degboé⁴, ¹Rheumatology Center, Purpan University Hospital, Toulouse, France, ²Rheumatology Department, Pellegrin University Hospital, BORDEAUX, France, ³Inserm U558, Rheumatology Center, Purpan University Hospital, Toulouse, France, ⁴Rheumatology, Rheumatology Center, Purpan University Hospital, Toulouse, France
Background/Purpose: Rheumatoid arthritis (RA) is associated with reduction of bone mineral density (BMD) and increased risk of peripheral and axial fractures. Methotrexate is the first-line…
Abstract Number: 1317 • 2015 ACR/ARHP Annual Meeting
Clinical Utility of Joint Space Width and X-Ray Radiogrammetry in RA: Markers for Early Radiographic Progression
Michael Platten¹, Yogan Kisten², Johan Kälvesten³, Kristina Forslind⁴ and Ronald F. van Vollenhoven⁵, ¹Medicine, Karolinska Institutet, Huddinge, Sweden, ²ClinTRID, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ³Sectra AB, Stockholm, Sweden, ⁴Department of Medicine, Helsingborgs Lasarett, Section of Rheumatology, Helsingborg, Sweden, ⁵Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden
Background/Purpose: Early prediction of radiographic progression is beneficial in rheumatoid arthritis (RA) patient management. The van der Heijde modified Sharp score (SHS) is currently the…
Abstract Number: 1706 • 2015 ACR/ARHP Annual Meeting
Prevalence and Factors Associated with Non-Traumatic Vertebral Fractures in Psoriatic Arthritis
Shelly Chandran¹, Sindhu R. Johnson², Angela Cheung³, David Salonen⁴ and Dafna Gladman⁵, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Dept of Rheumatology, Toronto Western and Mt. Sinai Hospitals, University of Toronto, Toronto, ON, Canada, ³Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁴Department of Medical Imaging, University Health Network, Toronto, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The prevalence of osteoporotic vertebral fractures (VF) in psoriatic arthritis (PsA) is not known. We aim to determine the prevalence and factors associated with…
Abstract Number: 344 • 2015 ACR/ARHP Annual Meeting
Results of a Phase 2 Clinical Trial to Evaluate the Effects of Romosozumab in Japanese Women with Postmenopausal Osteoporosis
H Ishibashi¹, DB Crittenden², A Miyauchi³, C Libanati⁴, J Maddox², L Chen² and A Grauer², ¹Ina Hospital, Saitama, Japan, ²Amgen Inc., Thousand Oaks, CA, ³Miyauchi Medical Center, Osaka, Japan, ⁴UCB Pharma, Brussels, Belgium
Background/Purpose: Romosozumab is a sclerostin inhibitor that rapidly increases bone mineral density (BMD) through a dual effect on bone, causing increased bone formation and decreased…
Abstract Number: 2149 • 2014 ACR/ARHP Annual Meeting
Relationship Between the Magnitude of Bone Formation in the Anterior Vertebral Corners, As Assessed through 18F-Fluoride Uptake, and Lumbar Spine Bone Mineral Density in Patients with Ankylosing Spondylitis
Seung-Geun Lee¹, Eun-Kyoung Park¹, Geun-Tae Kim², Sang-Yeob Lee³ and Joung-Wokk Lee⁴, ¹Divsion of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, South Korea, ⁴Divsion of Rheumatology, Department of Internal Medicine, Busan St. Marys center, Busan, South Korea
Background/Purpose: 18F-fluoride uptake represents active osteoblastic bone synthesis. We investigated the relationship between the magnitude of bone formation in anterior vertebral corners, as assessed through…
Abstract Number: 2013 • 2014 ACR/ARHP Annual Meeting
Quality Appraisal of Educational Websites on Osteoporosis and Bone Health
Maria A. Lopez-Olivo¹, Noha Abdel-Wahab^2,3, Abhinav Dodeja⁴, Gregory Pratt⁵ and Maria E. Suarez-Almazor², ¹Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³Rheumatology & Rehabilitation Department, Assiut University Hospital, Assiut, Egypt, ⁴The University of Texas Health Science Center, School of Public Health, Houston, TX, ⁵Research Medical Library, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Osteoporosis, like many other chronic diseases, can have better outcomes when informed patients get involved in self-management, resulting in better ourtcomes. Bone health education…
Abstract Number: 1818 • 2014 ACR/ARHP Annual Meeting
Subchondral Bone Mineral Density Improves Prediction of Knee Osteoarthritis Progression Compared with Clinical Factors Alone: Data from the Osteoarthritis Initiative
Michael P. Lavalley¹, Grace H. Lo², Lori Lyn Price³, Jeffrey Driban⁴, Charles Eaton⁵ and Timothy E. McAlindon⁶, ¹Biostatistics, Boston University, Boston, MA, ²VA HSR&D Center for Innovations in Quality, Effectiveness and Safety; Medical Care Line and Research Care Line; Department of Medicine, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX, ³Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, ⁴Tufts Medical Center, Boston, MA, ⁵Center for Primary Care and Prevention, Memorial Hospital of Rhode Island, Providence, RI, ⁶Division of Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose A prediction rule for knee osteoarthritis (OA) progression would have great clinical utility in identifying at-risk patients for intervention. Rules using clinically available measurements…
Abstract Number: 1795 • 2014 ACR/ARHP Annual Meeting
Denosumab Restores Cortical Bone Loss at the Distal Radius Associated with Aging and Reduces Wrist Fracture Risk: Analyses from the Cross-over Group in the Extension of the Denosumab Pivotal Fracture Trial
JP Bilezikian¹, CL Benhamou², CJF Lin³, JP Brown⁴, NS Daizadeh³, PR Ebeling⁵, A Fahrleitner-Pammer⁶, E Franek⁷, N Gilchrist⁸, PD Miller⁹, JA Simon¹⁰, I Valter¹¹, CAF Zerbini¹² and C Libanati³, ¹College of Physicians and Surgeons, Columbia University, New York, NY, ²CHR d'Orléans, Orléans, France, ³Amgen Inc., Thousand Oaks, CA, ⁴CHU de Québec Research Centre and Laval University, Quebec City, QC, Canada, ⁵Monash University, Clayton, Australia, ⁶Medical University, Graz, Austria, ⁷Medical Research Center, Polish Academy of Sciences, Warsaw, Poland, ⁸The Princess Margaret Hospital, Christchurch, New Zealand, ⁹Colorado Center for Bone Research, Lakewood, CO, ¹⁰George Washington University, Washington, DC, ¹¹Center for Clinical and Basic Research, Tallinn, Estonia, ¹²Centro Paulista de Investigação Clinica, São Paulo, Brazil
Background/Purpose: Cortical bone loss is a major determinant of increased fracture risk. Denosumab (DMAb) has been shown to increase BMD at sites of cortical bone,…
Abstract Number: 1490 • 2014 ACR/ARHP Annual Meeting
Can Tumor Necrosis Factor Inhibitors Protect Rheumatoid Arthritis Patients from Osteoporosis? Impact of Tumor Necrosis Factor Inhibitors on Bone Mineral Density and Bone Remodeling Markers
Anaïz Nutz¹, Yohan Duny², Thomas Barnetche³, Jacques Morel⁴, Bernard Combe⁵ and Claire Daien⁶, ¹Rheumatology, Hopital Lapeyronie, Montpellier, France, ²INSERM, Montpellier, France, ³Department of rheumatology, Bordeau, France, ⁴Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ⁵Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁶Hopital Lapeyronie, Montpellier, France
Background/Purpose Rheumatoid Arthritis (RA) is a chronic inflammatory disease characterized by joint and bone destruction. Loss of bone in RA is not only localized in…
Abstract Number: 1301 • 2014 ACR/ARHP Annual Meeting
Trabecular Bone Impairment Assessed By HR-pQCT in Juvenile-Onset Systemic Lupus Erythematous with Vertebral Fractures
Juliane Paupitz, Glauce Lima, Valéria Caparbo, Henrique Fuller, Eloisa Bonfa and Rosa M R Pereira, Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose The three-dimensional evaluation of bone by HR-pQCT has the advantage to provide assessment to not only bone density, but also to a noninvasive evaluation…
Abstract Number: 1246 • 2014 ACR/ARHP Annual Meeting
Assessment of Protective Factors of Bone Mineral Density in a New Orleans Sarcoidosis Population
McCall Walker¹, Harmanjot K. Grewal², Adam Janot³, Mary Yu⁴, Sophia Cenac⁵, Matthew R. Lammi^6,7 and Lesley Ann Saketkoo⁸, ¹LSUHSC School of Medicine, New Orleans, LA, ²Rheumatology, Lousiana State University Health Sciences Center, New Orleans, LA, ³Department of Ophthalmology, Virginia Commonwealth University –Medical College of Virginia, Charlottesville, VA, ⁴Internal Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, ⁵Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University Health Science Center, New Orleans, LA, ⁶Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, ⁷Section of Pulmonary and Critical Care Medicine, LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ⁸Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA
Background/Purpose: Sarcoidosis often involves pathological dysregulation of dependent factors of bone metabolism, e.g. calcitriol /calcium, and administration of high dose glucocorticoids (GCs) leading to low…

« Previous Page
1
…
8
9
10
11
12
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.